Search:

Filter:

Post type:

Sort:

Complaint, USA v John Thomas Howard, October 2026

November 16, 2026

United States District Court Western District of Virginia USA v John Thomas Howard Criminal Complaint Filed October 2026 Read the complaint and affidavit

PSM submits comment opposing HHS’s proposed peptide enforcement discretion policy

November 16, 2026

The policy would expose patients to unproven substances that FDA’s career staff recommended not be used in compounding because of safety and other concerns.

She trusted her med spa with a “pharmacy grade” treatment. No one mentioned risks.

November 13, 2026

Paige Gordon asked her med spa about a peptide treatment. No one reviewed her health history or talked about potential risks. Months later, her cancer came back.

November 9, 2026: Woman’s cancer returns after taking med spa peptides

November 12, 2026

Paige Gordon bought a peptide promising glowing skin on the recommendation of a licensed nurse she’d been a patient of for years at a med spa. Two months ago, she was told her cancer returned.

November 2, 2026: HHS tells compounders it will not enforce peptide regulations

November 3, 2026

The policy effectively allows compounders to produce these drugs, which are massively understudied, even though they don’t meet federal criteria for compounding.

Statement on the FDA and HHS enforcement discretion policy for 503a compounding with certain peptides

October 28, 2026

“Today’s decision leaves Americans in a grey area as to whether peptides are safe or not, even though the FDA’s own scientists recommended against voting in favor of these substances due to concerns with evidence.”

October 26, 2026: PSM files citizen petition asking FDA not to allow compounding of peptides

October 27, 2026

The peptides in question are untested and poorly defined, and making them easier to compound is a threat to public safety.

Case overview: Eli Lilly and Co v InstantRx, et al (2026 — ) – ongoing

October 26, 2026

Eli Lilly filed a complaint against InstantRx and other defendants that allegedly distributed counterfeit and/or misbranded versions of Lilly-branded medicines through online pharmacy to pharmacy marketplaces.

October 19, 2026: Two deaths linked to bootlegged retatrutide

October 21, 2026

Two deaths have been linked to black market versions of retatrutide, as a British woman warns followers that taking an early dose of the drug “nearly killed” her.

Partnership for Safe Medicines files Citizen Petition urging FDA to block compounding of unapproved and uncharacterized peptides

October 21, 2026

The Partnership for Safe Medicines (PSM) filed a citizen petition urging the U.S. Food and Drug Administration to block compounding of unapproved peptides and to disregard the advisory committee vote that recommended allowing them.